Renovaro Inc. (RENB)
NASDAQ: RENB · Real-Time Price · USD
0.3089
-0.0039 (-1.25%)
At close: Jun 6, 2025, 4:00 PM
0.3050
-0.0039 (-1.26%)
After-hours: Jun 6, 2025, 7:57 PM EDT
Renovaro Employees
Renovaro had 25 employees as of June 30, 2024. The number of employees increased by 13 or 108.33% compared to the previous year.
Employees
25
Change (1Y)
13
Growth (1Y)
108.33%
Revenue / Employee
n/a
Profits / Employee
-$2,369,248
Market Cap
53.17M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
RENB News
- 5 days ago - Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform - GlobeNewsWire
- 16 days ago - UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - GlobeNewsWire
- 17 days ago - Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology - GlobeNewsWire
- 25 days ago - Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform - GlobeNewsWire
- 26 days ago - Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics - GlobeNewsWire
- 6 weeks ago - Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs - GlobeNewsWire
- 2 months ago - Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine - GlobeNewsWire
- 2 months ago - Renovaro Provides Update to Definitive Agreement with Predictive Oncology - GlobeNewsWire